Convelo Therapeutics, Inc.
Name
Convelo is from a Latin word meaning "to wrap around".
Values
At Convelo, we strive for scientific excellence regardless of how great the challenge. The force that inspires and drives us is our commitment to providing innovative and life-changing medicines for patients and their families.
History
Convelo Therapeutics was founded in 2016 by Case Western Reserve University School of Medicine professors Paul Tesar, PhD and Drew Adams, PhD to translate discoveries from their laboratories into medicines for critically ill patients.
In 2018, Convelo announced the closing of $7.8M in funding led by Cleveland Convelo Holdings, LLC. Concurrently, Convelo announced that biotech pioneer Derrick Rossi, PhD was appointed as President and CEO.
In 2019, Convelo entered into a research partnership with Genentech to discover and advance potent, safe and effective remyelinating therapeutics for multiple sclerosis.
In 2022, Convelo closed a $12M series B round led by Cleveland Convelo Holdings, LLC, with participation from JumpStart, Inc.
As of 2023, Convelo has grown to 17 employees occupying a 2,000+ sq ft R&D laboratory within the University Circle district of Cleveland, Ohio.